Ivana Rubino

Company: Biogen

Job title: Vice President & Head of Global Medical Neuropsychiatry & Alzheimer's disease

Seminars:

Panel Discussion: What Have we Learned from the Last 12 Months of Alzheimer’s Drug Development? 8:15 am

What have been the main obstacles to integrating first class of anti-amyloids into the treatment paradigm? What is the impact of ARIA on penetration of these new anti-amyloid therapies into market? What is the plan to better manage the burden of ARIA going forward? Shifting focus to new emerging therapies: From anti-inflammatory and anti-tau treatments…Read more

day: Conference Day One AM

Highlighting Insight Gained from the Development of the First Generation of Anti-Amyloids & Efforts to Bolster Innovation in New Modalities & Targets 9:00 am

Reviewing what we’ve learned from the first generation of anti-amyloids and where extra effort is needed to enhance their RoA and manage burdens of ARIA Exploring gaps in our understanding of ARIA that may warrant additional work Future directions for the development of new modalities and targets beyond amyloid to address unmet patient needsRead more

day: Conference Day One AM